Clinical implications of cytogenetic and molecular analyses of pediatric acute lymphoblastic leukemia

Stem Cells
W M Crist, C H Pui

Abstract

The prognosis for children with acute lymphoblastic leukemia (ALL) has improved steadily over the past 20 years. Today, at least two-thirds of newly diagnosed cases are curable with intensified risk-based therapy. The challenge now is to identify, prior to or early in treatment, the one-third of patients who are destined to relapse, so that alternative therapy can be introduced sooner. Cytogenetic studies of lymphoblasts have identified recurring abnormalities of prognostic importance and pinpointed chromosomal regions for molecular analyses. Recently, molecular diagnostic techniques have been developed for the more common cytogenetic subgroups of ALL, defined by the t(1;19) and t(9;22) chromosomal translocations (approximately 10% of cases). Polymerase chain reaction (PCR) techniques can identify these clinically important subgroups in the absence of successful cytogenetic studies. PCR analysis also provides a sensitive and specific tool for the detection of minimal residual disease during apparent (clinically defined) remission. Additionally, molecular studies of cases with specific cytogenetic lesions have helped to clarify the events leading to leukemic transformation of normal lymphoid cells. It is reasonable to expect tha...Continue Reading

References

Dec 1, 1992·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·R WassermanG Rovera
Apr 1, 1992·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·R TrueworthyM Haggard
Jul 1, 1992·Annals of Hematology·S M Sanal, M Gur-Lavi
Sep 25, 1991·JAMA : the Journal of the American Medical Association·L J SteinherzM L Murphy
Dec 12, 1991·The New England Journal of Medicine·C H PuiJ T Sandlund
Mar 21, 1991·The New England Journal of Medicine·S E LipshultzS P Sanders
Aug 1, 1990·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·S C RaimondiG K Rivera
Jan 1, 1989·Annual Review of Medicine·S S ClarkO N Witte
Mar 1, 1985·European Journal of Epidemiology·C M Croce

❮ Previous
Next ❯

Citations

Jun 1, 1996·Genes, Chromosomes & Cancer·W H RaskindM Matsushita
Jan 1, 1996·Journal of Cancer Research and Clinical Oncology·R AnkathilM K Nair
Aug 4, 2011·Journal of Multidisciplinary Healthcare·Mary Ann Cantrell, Kathy Ruble
Jan 1, 1994·Micron : the International Research and Review Journal for Microscopy·M Klobusická
Jun 1, 1994·Baillière's Clinical Haematology·G K Rivera

❮ Previous
Next ❯

Related Concepts

Related Feeds

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.

Related Papers

Journal of Pediatric Oncology Nursing : Official Journal of the Association of Pediatric Oncology Nurses
Nancy E Kline
Journal of Pediatric Oncology Nursing : Official Journal of the Association of Pediatric Oncology Nurses
Ellen TracyRichard B Womer
Primary Care
Christopher P Raab, J Carlton Gartner
© 2021 Meta ULC. All rights reserved